Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

| Form 4 | THERAPEUTIC | S INC | | | | | | | | | |
|--|---|--|---|--|---|--------|---------|---|--|---|--|
| FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | - | PPROVAL 3235-0287 | | | |
| Check thi if no long subject to Section 14 Form 5 obligation may conti <i>See</i> Instru 1(b). | 6. Filed purs Section 17(a | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section | | | | | | | | Expires:January 31, 2005Estimated average burden hours per response0.5 | |
| (Print or Type R | Responses) | | | | | | | | | | |
| OMENN GILBERT S Syn | | | | Name and TIN THE | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | |
| | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/12/2015 | | | | | X_ Director 10% Owner Officer (give title Other (specify below) below) | | | |
| | | | | ndment, Date Original th/Day/Year) | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | | |
| NORCROSS | | | | | | | | Person | | porting | |
| (City) | (State) (| Zip) | Table | e I - Non-Do | erivative S | ecurit | ies Acq | uired, Disposed o | f, or Beneficial | lly Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deen Executior any (Month/D | n Date, if | 3. Transactio Code (Instr. 8) Code V | 4. Securiti m(A) or Dis (D) (Instr. 3, 4 Amount | sposed | of | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4) | | |
| Common Stock | 03/12/2015 | | | А | 11,112 | A | \$0 | 40,121 | D | | |
| Common Stock | 04/07/2015 | | | А | 1,506 | A | \$0 | 41,627 | D | | |
| Common Stock | 04/08/2015 | | | А | 25,934 | А | \$0 | 67,561 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not

(9-02)

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. 5. Number of Transactio/Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | 8 D S (1 |
|---|---|---|---|--|---------|--|--------------------|---|-------------------------------------|-------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | |
| Stock Option (right to buy) | \$ 5.06 | 04/08/2015 | | D | 28,323 | <u>(1)</u> | 09/23/2024 | Common Stock | 28,323 | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | |
|---|---------------|-----------|---------|-------|--|--|
| | Director | 10% Owner | Officer | Other | | |
| OMENN GILBERT S C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS, GA 30071 | X | | | | | |
| Signatures | | | | | | |
| /s/ Jack W. Callicutt as Power of Attorney for Gilbert S Omenn | | 07/08/ | /2015 | | | |
| **Signature of Reporting Person | | Dat | e | | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25,071 options vested upon grant and 3,252 options vested ratably through February 11, 2015.

The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received
 (2) 25,934 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on September 23, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.